Thenappan Chandrasekar, M.D.
Associate Professor, Department of Urology
To see if Thenappan Chandrasekar is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Specialties
Urologic Oncology
Minimally Invasive Surgery
Genitourinary Cancers
Urologic Surgery
Department
Locations and Contact
Lawrence J. Ellison Ambulatory Care Center
Lawrence J. Ellison Ambulatory Care Center
4860 Y St.
Sacramento, CA 95817
Phone: 916-734-2222
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Phone: 916-734-5959
Philosophy of Care
Having experienced UC Davis as a patient myself, I understand the vulnerable position that patients and their families are in. This can be a confusing and troubling time and it is my goal to ensure that my patients and their families are well informed and supported during this difficult time.
Thorough communication is critical to determine optimal, individualized management strategies for each patient. I will work to ensure that every patient and key family members fully understands his or her medical condition before embarking on various treatments.
Every treatment decision must be taken in the context of each patient's medical, social, and family environment. As such, I balance each patient's condition within their personal situation to help tailor care.
Clinical Interests
Dr. Chandrasekar specializes in the management of malignant disease of the urinary tract.
The specialty care Dr. Chandrasekar offers includes:
- Multi-disciplinary and comprehensive care of patients with urologic malignancy
- Active surveillance for low risk prostate cancer and kidney masses/cysts
- Multi-parametric MRI/US fusion targeted prostate biopsy
- Blue Light Fluorescent cystoscopy for bladder cancer with Cysview
- Minimally invasive and robotic surgery of the kidney, prostate, bladder, adrenal gland including prostatectomy with nerve sparing, partial/radical nephrectomy, pyeloplasty/ureteral reconstruction, and cystectomy
- Urinary diversion (ileal conduit and neobladder creation)
- Advanced genomics testing of urologic cancers
Research/Academic Interests
Dr. Chandrasekar has a research interest focused on improving care in the field of bladder and kidney cancer, both areas ripe for major change. He has a strong background in health sciences research, working with large datasets to help address major disparities in healthcare delivery and outcomes. Finally, he has an ongoing interest in optimizing the evaluation and managenent of complex renal cysts, which are often overtreated.
Division
Urology
Center/Program Affiliation
Undergraduate School
B.S., Life Sciences, Penn State University, State College PA 2005
Medical School
M.D., Jefferson Medical College/Sidney Kimmel Medical College, Philadelphia PA 2010
Internship
General Surgery, UC Davis Medical Center, Sacramento CA 2010-2012
Residency
Urology, UC Davis Medical Center, Sacramento CA 2012-2016
Fellowship
Robotics (Department of Urology), Thomas Jefferson University Hospital, Philadelphia PA 2018-2019
Fellowship
Urologic Oncology, University of Toronto, Toronto, ON, Canada 2016-2018
Best Poster in Session, American Urological Association Conference, 2022
Paper of the Year Award, SUO - Young Urologic Oncologists (YOU), 2018
Clinical Fellow Teaching Award, 2018
Third Place (Clinical Science), Northern California Urological Resident Seminar, 2016
First Place (Basic Science), Northern California Urological Resident Seminar, 2015
For full bibliography, please go to: https://www.ncbi.nlm.nih.gov/myncbi/1HA7G-pVwy_Ql/bibliography/public/
Chandrasekar T, et al. Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass. Eur Urol. 2021 Nov;80(5):575-588. PMID: 33558091.
Chandrasekar T, Bowler N, Schneider A, Goldberg H, Mark JR, Trabulsi EJ, Lallas CD, Gomella LG. Outcomes of Active Surveillance for Men With Intermediate Risk Prostate Cancer: A Population-Based Analysis. Urology. 2021 Sep;155:101-109. doi:10.1016/j.urology.2021.05.068. Epub 2021 Jun 27. PMID:34186134.
Chandrasekar T, Kelly WK, Gomella LG. Overview of Prostate Cancer Genetic Testing. Urol Clin North Am. 2021 Aug;48(3):279-282. doi:10.1016/j.ucl.2021.04.002. Epub 2021 Jun 10. PMID:34210484.
Chandrasekar T, Han TM, Glick L, Leong JY, Teplitsky S, Noorani R, Goldberg H, Klaassen Z, Wallis CJD, Mark JR, Trabulsi EJ, Lallas CD, Gomella LG. Setting the Standards: Examining Research Productivity Among Academic Urologists in the USA and Canada in 2019. Eur Urol Focus. 2021 Mar;7(2):489-496. doi:10.1016/j.euf.2020.02.003. Epub 2020 Feb 26. PMID:32113885.
Giri VN, et al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 Aug 20;38(24):2798-2811. doi:10.1200/JCO.20.00046. PMID:32516092.
Chandrasekar T, Gross L, Gomella LG, Hegarty SE, Leong JY, Giri VN. Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men. Eur Urol Oncol. 2020 Jun;3(3):291-297. doi:10.1016/j.euo.2019.06.010. Epub 2019 Jul 3. PMID:31278035.
Wallis CJD, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. 2018 Jun;73(6):834-844. doi:10.1016/j.eururo.2017.10.002. PMID:29037513.
Chandrasekar T, Klaassen Z, Goldberg H, Kulkarni GS, Hamilton RJ, Fleshner NE. Metastatic renal cell carcinoma: Patterns and predictors of metastases-A contemporary population-based series. Urol Oncol. 2017 Nov;35(11):661.e7-661.e14. doi:10.1016/j.urolonc.2017.06.060. Epub 2017 Jul 17. PMID:28728748.
Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015 Jun;4(3):365-80. doi:10.3978/j.issn.2223-4683.2015.05.02. PMID:26814148.